Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

ALPHARETTA, Ga., April 27, 2023 -- Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space ,... | April 27, 2023

Related Keywords

Massachusetts ,United States ,Canada ,China ,India ,South Korea ,New Zealand ,Australia ,Triamcinolone Acetonide Suprachoroidal ,Remy Bernarda ,Dennism Marcus ,George Lasezkay ,Peter Yuwei Chang ,Jenny Kobin ,Surgery Institution ,Exchange Commission ,Nasdaq ,Md Southeast Retina Center ,Preclinical Development ,Association For Research ,Clearside Biomedical Inc ,Va Physician ,Massachusetts Eye Research ,Globenewswire Inc ,Company Publications ,Drug Administration ,Chief Executive ,Extension Study ,Tolerability Study ,Suprachoroidal Injection ,Persistent Activity Following ,Vice President ,Early Adoption ,Triamcinolone Acetonide Suprachoroidal Injection ,Uveitic Macular Edema ,Physician Survey ,Yuwei Chang ,Eye Research ,Tolerability Results ,All Cohorts ,Month Extension Study ,Optical Coherence Tomography ,Suprachoroidal Space ,Injection Platform ,Neovascular Age Related Macular Degeneration ,Arctic Vision ,Safety Information ,Private Securities Litigation Reform Act ,Annual Report ,Periodic Reports ,Media Contacts ,Clearside Biomedical ,Nc Stock Exchange ,News ,Information ,Press Release ,Pril ,023 ,Learside ,Iopharmaceutical ,Company ,Revolutionizing ,The ,Delivery ,F ,Therapies ,O ,Back ,Eye ,Through ,Uprachoroidal ,Pace Clsd Us1850631045 ,